Published 4 months ago

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More - ATAI Life Sciences (NASDAQ:ATAI), Clearmind Medicine (NASDAQ:CMND)

Summary by Ground News

The U.S. Department of Veterans Affairs (VA) is launching new studies on using psychedelic compounds to treat post-traumatic stress disorder (PTSD) and depression among military veterans. This new VA-backed effort will delve deeper into "the effectiveness and safety of using MDMA and psilocybin-augmented psychotherapy in veterans"

0 Articles

All

Left

Center

Right

Benzinga

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More - ATAI Life Sciences (NASDAQ:ATAI), Clearmind Medicine (NASDAQ:CMND)

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation has secured over $100 million in a Series A private stock sale. The funds will support the final stages of its application for regulatory approval to sell MDMA, also known as ecstasy, as a t…

4 months ago·New York, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.